Monoclonal Antibody therapy reduces disease severity and chances of death in high-risk individuals infected with the Delta, as per the study of AIG Hospitals.
Delta Variant of COVID-19 can now be treated 100 percent by Monoclonal Antibody therapy, as the therapy has been proven effective in reducing disease severity and chances of death in high-risk individuals infected by the variant, as per the findings of Hyderabad-based AIG Hospital. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on pathogens.
Thanks for sharing this positive and encouraging news of India's involvement in the research of monoclonal antibody treatment for COVID-19. The treatment that was used in this study is the monoclonal antibody treatment called Ronapreve (Regen-COV).
Here's a link to the research letter about the study that was printed in the Journal of Internal Medicine and gives further detail:
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.